Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453323 | 0.80 | ALDH1A1 (0.36) | L3MBTL1ATRNPSR1ALDH1A1KDM4E | |
| SCHEMBL617804 | 0.79 | NPSR1 (0.35) | L3MBTL1ATRNPSR1ALDH1A1KDM4E | |
| SCHEMBL21855448 | 0.78 | L3MBTL1 (0.48) | L3MBTL1ATRALDH1A1KDM4ELMNA | |
| SCHEMBL14221249 | 0.78 | PDPK1 (0.33) | ALDH1A1PDPK1MKNK2SSTR4SYK | |
| SCHEMBL30781550 | 0.77 | ATR (0.40) | L3MBTL1ATRNPSR1ALDH1A1KDM4E | |
| SCHEMBL25223691 | 0.77 | NPSR1 (0.33) | ATRNPSR1ALDH1A1LMNAPDPK1 | |
| SCHEMBL7455268 | 0.77 | PDPK1 (0.36) | ATRNPSR1ALDH1A1LMNAPDPK1 | |
| SCHEMBL10325314 | 0.77 | NPSR1 (0.33) | ATRNPSR1ALDH1A1LMNAPDPK1 | |
| SCHEMBL22582911 | 0.76 | ATR (0.40) | ATRALDH1A1LMNAPDPK1SSTR4 | |
| SCHEMBL30883874 | 0.76 | ATR (0.39) | L3MBTL1ATRNPSR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858862-B1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-7947685-B2 | Pyrazine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2009-09-17 | — | — | US | disclosed |
| US-20060199828-A1 | Pyrazine-2-carboxyamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | L3MBTL1 1350/4885ATR 3759/4885NPSR1 150/4885 |
| US-20060199828-A1 | Pyrazine-2-carboxyamide derivatives | CNR2, CNR1, CHRNA2 | L3MBTL1 1350/4885ATR 3759/4885NPSR1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.